Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ELCC 2019 | IMpower150: efficacy outcomes of atezolizumab addition in pre-treated EGFR-mutated NSCLC

Martin Reck, MD, PhD, from Lung Clinic Grosshansdorf, Grosshansdorf, Germany, gives us the latest updates on the IMpower150 trial (NCT02366143) from the European Lung Cancer Congress (ELCC) 2019, held in Geneva, Switzerland. This trial investigated atezolizumab in combination with carboplatin and paclitaxel with or without bevacizumab, compared with carboplatin/paclitaxel/bevacizumab in stage IV non-squamous non-small cell lung cancer (NSCLC). Here, the efficacy outcomes for the addition of atezolizumab to the treatment of pre-treated EGFR-mutated NSCLC are presented.